Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

GLG News by Sutent Prescribers for RCC: Oncologists (US)

Donald Fleming, Division Head of Hematology and Oncology

Donald FlemingDivision Head of Hematology and OncologyDAVIS HEALTH SYSTEM INC What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Omapro will fill a CML void

November 14, 2009

US FDA accepts ChemGenex's Omapro NDA filing to treat CML, grants priority review status | www.pharmabiz.com

Patients with CML have a good prognosis when treated with TKI's An exception is the ones that develope a particular mutation known as T315IOnly SCT seems to be effective in this group of patients and maybe too morbid of therapy for many patients

Donald Fleming, Division Head of Hematology and Oncology

Donald FlemingDivision Head of Hematology and OncologyDAVIS HEALTH SYSTEM INC What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Triple negative Breast Cancer Strategies

October 14, 2009

MediGene completes patient recruitment into EndoTAGTM-1 phase II breast cancer trial | www.pharmabiz.com

Triple negative Breast cancer has been a phenotype with little hope up until recentlyWhile advances in hormonal therapy and Her2 blocking agents has revolutionized ER/PR + and Her 2 positive breast cancer therapy, triple negative breast cancer pulls down the outcomes, with similar responses as for non small cell lung cancer

Donald Fleming, Division Head of Hematology and Oncology

Donald FlemingDivision Head of Hematology and OncologyDAVIS HEALTH SYSTEM INC What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Farletuzumab (F) helps the ovarian cancer patients that do well, do well?

September 25, 2009

Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects | www.pipelinereview.com

F recently demonstrated a great majority of platinum sensitive patients respond when given in combination with a platinum based regimen in recurrent ovarian caPlatinum sensitive patients typically do well with platinum based intervention, but it's the platinum resistant ( denovo or delayed) that we have a problem with

Donald Fleming, Division Head of Hematology and Oncology

Donald FlemingDivision Head of Hematology and OncologyDAVIS HEALTH SYSTEM INC What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Herceptin for Her2 + gastric cancer, If you can find one

September 25, 2009

Roche's Herceptin provides impressive survival benefit in HER2-positive advanced gastric cancer | www.pharmabiz.com

Herceptin recently reported in Phase II ASCo data to enhance chemo in Her 2 positive gastric cancer

Donald Fleming, Division Head of Hematology and Oncology

Donald FlemingDivision Head of Hematology and OncologyDAVIS HEALTH SYSTEM INC What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

REGORAFENIB joins a crowd of TKI's for RCC

September 25, 2009

Bayer's anti-cancer drug regorafenib shows stabilization or regression in 81% of kidney cancer patients | www.pharmabiz.com

RCC now has multiple TKI"S either approved or in development for txThe disease control rate seems to be a popular and effective endpoint to get drugs for RCC approved

Donald Fleming, Division Head of Hematology and Oncology

Donald FlemingDivision Head of Hematology and OncologyDAVIS HEALTH SYSTEM INC What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Pay for performance Medicare "reform"

May 4, 2009

Medicare System Overhaul Proposed by Two Senators | www.nytimes.com

Medicare will reward based on outcome Medicare will pay for chronic illness acre based on outcome results Be careful about heading towards cancer care rationing

Donald Fleming, Division Head of Hematology and Oncology

Donald FlemingDivision Head of Hematology and OncologyDAVIS HEALTH SYSTEM INC What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Alimta potential In India

February 27, 2009

Intas Biopharma to market Pemetrexed in India soon | www.pharmabiz.com

Alimta has been approved as upfront treatemnt of NSCLCA with platinum Alimta approved US as  single agent salvage treatment NSCLCa Market share IN US hsa been crowded out by other platinum combinations

Donald Fleming, Division Head of Hematology and Oncology

Donald FlemingDivision Head of Hematology and OncologyDAVIS HEALTH SYSTEM INC What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

tarceva adds to avastin but avastin doesn't add to tarceva?

February 17, 2009

OSI, Genentech Say Cancer Drug’s Benefits Ends Trial (Update2) | www.bloomberg.com

Beta lung demonstrated no benefit of adding avastin to tarceva as second line advanced lung cancer therapy Atals trial demonstrates adding tarceva to avastin after chemo in advanced lung cancer does benefit

Donald Fleming, Division Head of Hematology and Oncology

Donald FlemingDivision Head of Hematology and OncologyDAVIS HEALTH SYSTEM INC What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

More may or may not be better in colorectal cancer

February 6, 2009

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer | nejm.highwire.org

Recent trial such as PACE and CAIRO imply combo biologics are not helpful Is it likely this will hold true in future situations?

Donald Fleming, Division Head of Hematology and Oncology

Donald FlemingDivision Head of Hematology and OncologyDAVIS HEALTH SYSTEM INC What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Plitidepsin ( Aplidin) helps in PTCL patients

January 19, 2009

PharmaMar announces the extension of Phase II trial with Aplidin(R) in Peripheral T-Cell Lymphoma after the excellent preliminary results | www.pipelinereview.com

New drug plitidepsin has anti tumor effects in PTCL patients PTCL is a relatively rare NHL form of NHL Plitidepsin has much more financial potential outside of NHL

Page : 12345678910Next1 to 10 of 106

Leading institutions connect with members of the Healthcare councils through GLG

Most Popular Healthcare News